Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  afatinib dimaleate
Find trials that include:  Any drugs shown
Results 1-10 of 10 for your search:
Start Over
Afatinib Dimaleate with or without Cetuximab in Treating Patients with Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: S1403, NCI-2014-02405, NCT02438722
LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 1200.131, NCI-2012-02044, 2011-000392-14, NCT01345669
Afatinib Dimaleate and Trastuzumab in Treating Patients with Refractory Metastatic Esophagus or Stomach Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11-166, NCI-2012-00414, NCT01522768
Afatinib Dimaleate, Combination Chemotherapy, and Radiation Therapy in Treating Patients with Stage III Non-small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-464, NCI-2012-01535, 1200.158, NCT01553942
Afatinib Dimaleate in Treating Patients with Stage I-III Non-small Cell Lung Cancer That Was Removed by Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-504, NCI-2013-01108, NCT01746251
Afatinib Dimaleate in Treating Patients With Advanced Refractory Urothelial Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-0540/ 1200.171, NCI-2014-00859, IRB13-0540, NCT02122172
Afatinib and Paclitaxel in Treating Patients with HER2-Positive Recurrent Advanced Gastric, Gastroesophageal Junction, or Esophageal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAM5905, NCI-2015-00758, 1200.203, NCI-2014-02350, NCT02274012
A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 1200.121, NCI-2012-01387, NCT01647711
Afatinib Dimaleate and Dasatinib in Treating Patients with Advanced or Recurrent Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MCC 17176, NCI-2014-00003, 1200.166, BI 1200.166, BMS CA180-379, CA180-379, NCT01999985
Start Over